Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of $30.59M rose 107.7% year over year, behind the +457.2% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -35.6% a year.

Context

  • Net change in cash amounted to 126447.2% of revenue in FY2025, up 63096.4 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +107.7% toward the trailing-twelve-month pace of +457.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.59M+148.3% QoQ
Last fiscal yearDec 2025
-$45.52M+17.8% YoY
LTMMar 2026
-$29.66M+457.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+107.7%——
1 year+17.8%——
3-year CAGR-35.6%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(45.52M) USD
Year-over-year change
-17.8%

Net Change in Cash vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +457.2% is the highest of 10, against a peer median of -65.0%.
  • Net change in cash amounts to 95683.9% of revenue for LYEL, versus a peer median of 262.0%.
LYEL Competitors
Net Change in Cash for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$156.79M USD+274.7%——
SLNSilence Therapeutics plcLTM Mar 2026$59.21M USD—+49.3%6425.7%
LYELLyell Immunopharma, Inc.LTM Mar 2026$29.66M USD+457.2%-35.6%95683.9%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$24.68M USD-85.3%——
EDITEditas Medicine, Inc.LTM Mar 2026$16.25M USD-123.4%—42.0%
CABACabaletta Bio, Inc.LTM Mar 2026$15.2M USD-65.0%+25.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$14.65M USD+134.8%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.15M USD+41.5%-40.4%—
AMRNAmarin Corporation plcLTM Mar 2026$11.44M USD+112.1%—5.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 9.36M CHF-77.8%-54.0%262.0%
GNLXGenelux CorporationLTM Mar 2026$6.93M USD-157.1%-7.6%86662.5%
Peer median (excluding LYEL) —-65.0%-7.6%262.0%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.